Telix agreed to acquire ITM Isotope Technologies Munich in a deal valued at about $1.65 billion upfront, according to the reported terms tied to its lead radiopharmaceutical development and an additional potential payment contingent on milestones. The transaction is designed to strengthen Telix’s R&D pipeline and expand supply capacity. The acquisition targets an R&D line described as sitting in Novartis’ radiopharmaceutical territory, alongside efforts to build out a radiopharma supply network. Analysts highlighted potential strategic value, describing the stock reaction as driven by improved competitive positioning in a field dominated by a small number of large developers. The merger further consolidates capacity in PET and targeted radioligand development as customers seek reliable sourcing and near-term commercial scale.